Form 4: Immix Biopharma CFO Buys Shares

Immix Biopharma's CFO and Director, Gabriel S. Morris, acquired 2,600 shares of common stock at $1.97 per share.

Summary

• Gabriel S. Morris, CFO and Director of Immix Biopharma, Inc. (IMMX), reported an acquisition of common stock.
• The transaction occurred on September 16, 2025.
• Morris purchased 2,600 shares of common stock at a price of $1.97 per share.
• Following this transaction, Morris directly owns 290,659 shares of common stock.
• He also indirectly beneficially owns 270,844 shares through Alwaysraise LLC and 24,141 shares through Alwaysraise Ventures I, LP, where he serves as Managing Partner.
• Morris disclaims beneficial ownership of the indirectly held securities except to the extent of his pecuniary interest.

Sentiment

Score: 8

Explanation: The direct purchase of company stock by a key executive like the CFO and Director is a strong positive signal, indicating management's belief in the company's prospects and potentially undervalued stock.

Positives

• Insider buying by a key executive (CFO and Director) signals confidence in the company's future prospects.
• The purchase of 2,600 shares at $1.97 per share represents a direct investment by management.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May see increased confidence due to insider buying, potentially leading to positive sentiment and share price movement.
• Employees: May perceive management's commitment to the company's success.

Key Dates

Recommendation

The direct purchase of company shares by a high-ranking insider like the CFO and Director, Gabriel S. Morris, signals strong conviction in the company's future performance and intrinsic value. Such insider buying often precedes positive developments or indicates a belief that the stock is currently undervalued, making it an attractive entry point for investors.

Keywords

Immix Biopharma, IMMX, Gabriel Morris, Insider Trading, Form 4, Stock Purchase, CFO, Director, Biopharma